MX2011008413A - Tratamientos mejorados para migraña basados en mimeticos de grelina. - Google Patents

Tratamientos mejorados para migraña basados en mimeticos de grelina.

Info

Publication number
MX2011008413A
MX2011008413A MX2011008413A MX2011008413A MX2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A
Authority
MX
Mexico
Prior art keywords
enhanced
treatments based
migraine
migraine treatments
ghrelin mimetics
Prior art date
Application number
MX2011008413A
Other languages
English (en)
Inventor
William J Polvino
Original Assignee
Helsinn Therapeutics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Therapeutics Us Inc filed Critical Helsinn Therapeutics Us Inc
Publication of MX2011008413A publication Critical patent/MX2011008413A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona a un método para mejorar la absorción de medicaciones para migraña y de esta manera tratar migrañas al co-administrar a un sujeto en necesidad del mismo una cantidad efectiva de un mimético de grelina o sal, hidrato o solvato farmacéuticamente aceptable del mismo y por lo menos una medicación para migraña seleccionada de un agonista de receptor de serotonina 5-HT1B/1D, un derivado de triptamina, un derivado de ergolina, un fármaco antiinflamatorio no esteroidal o un analgésico, o cualquier combinación de los mismos.
MX2011008413A 2009-02-27 2010-03-01 Tratamientos mejorados para migraña basados en mimeticos de grelina. MX2011008413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15612909P 2009-02-27 2009-02-27
PCT/US2010/025725 WO2010099522A1 (en) 2009-02-27 2010-03-01 Enhanced migraine treatments based on ghrelin mimetics

Publications (1)

Publication Number Publication Date
MX2011008413A true MX2011008413A (es) 2011-09-22

Family

ID=42144981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008413A MX2011008413A (es) 2009-02-27 2010-03-01 Tratamientos mejorados para migraña basados en mimeticos de grelina.

Country Status (17)

Country Link
US (2) US8486976B2 (es)
EP (1) EP2400986B1 (es)
JP (1) JP6041491B2 (es)
KR (2) KR20160136473A (es)
CN (1) CN102333545B (es)
AU (1) AU2010217792B2 (es)
BR (1) BRPI1008698A2 (es)
CA (1) CA2752813C (es)
EA (1) EA021055B1 (es)
ES (1) ES2558701T3 (es)
IL (1) IL214443A0 (es)
MX (1) MX2011008413A (es)
NO (1) NO20111303A1 (es)
SG (1) SG174158A1 (es)
TW (1) TWI457331B (es)
UA (1) UA105657C2 (es)
WO (1) WO2010099522A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281701A1 (en) * 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
JP2012529510A (ja) * 2009-06-12 2012-11-22 ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド イパモレリンジアセタートの注射用および輸液用の溶液
WO2013095707A1 (en) * 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138008A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
KR20220027884A (ko) * 2019-05-31 2022-03-08 레터럴 아이피 피티와이 리미티드 펩티드 및 그의 용도
JP2022546162A (ja) * 2019-08-30 2022-11-04 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281963B6 (sk) * 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
DE69637855D1 (de) * 1995-12-22 2009-04-16 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
EP1184370B1 (en) * 1996-07-22 2005-09-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2348979A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
DE60022683D1 (de) * 1999-12-28 2005-10-20 Kaken Pharma Co Ltd Nervenschutzmittel
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
WO2005097261A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
JP2009535336A (ja) 2006-04-25 2009-10-01 コーワ ファーマシューティカルズ アメリカ，インコーポレイティド 片頭痛治療用の固定組合せ剤形
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法

Also Published As

Publication number Publication date
US20130289068A1 (en) 2013-10-31
JP6041491B2 (ja) 2016-12-07
US8486976B2 (en) 2013-07-16
EA021055B1 (ru) 2015-03-31
KR20160136473A (ko) 2016-11-29
US20100222388A1 (en) 2010-09-02
TWI457331B (zh) 2014-10-21
KR20110126155A (ko) 2011-11-22
US8673947B2 (en) 2014-03-18
CA2752813C (en) 2017-03-28
NO20111303A1 (no) 2011-09-26
CN102333545A (zh) 2012-01-25
EP2400986A1 (en) 2012-01-04
CN102333545B (zh) 2014-03-19
BRPI1008698A2 (pt) 2016-03-08
KR101707666B1 (ko) 2017-02-16
EA201171091A1 (ru) 2012-04-30
CA2752813A1 (en) 2010-09-02
SG174158A1 (en) 2011-10-28
JP2012519184A (ja) 2012-08-23
UA105657C2 (uk) 2014-06-10
AU2010217792B2 (en) 2015-10-22
IL214443A0 (en) 2011-09-27
EP2400986B1 (en) 2015-10-14
TW201035071A (en) 2010-10-01
WO2010099522A1 (en) 2010-09-02
AU2010217792A1 (en) 2011-08-25
ES2558701T3 (es) 2016-02-08

Similar Documents

Publication Publication Date Title
MX2011008413A (es) Tratamientos mejorados para migraña basados en mimeticos de grelina.
EA200970369A1 (ru) Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака
WO2006055854A3 (en) Methods for reducing the side effects associated with mirtazapine treatment
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
MX2021014508A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
TN2011000239A1 (en) Hsp90 inhibitor combinations
WO2011162989A3 (en) Glp-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX2011006790A (es) Composiciones para administracion de farmacos.
BR112017003570A2 (pt) tratamento de combinação de inibidores de sglt2 e agonistas de dopamina para prevenir distúrbios metabólicos em animais equinos
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
EA201490268A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
WO2010031521A3 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
WO2009129432A3 (en) Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
MX2019004096A (es) Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion.
CO6361995A2 (es) Derivados de isoquinolinona como antagonistas de nk3
MX2009005798A (es) Recuperacion de apoplejia.
WO2009155139A9 (en) Use of isoindoles for the treatment of neurobehavioral disorders
MX2009012427A (es) Derivados de la espirociclopropil piperidina.
MX2013008269A (es) Composicion farmaceutica que comprende derivados de piridona.
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
MA32933B1 (fr) Combinaison d'inhibiteurs de hspo90 et d'herceptine
WO2009103218A8 (zh) 亚乙基肼酰胺类衍生物、其制备方法及其在医药上的应用
WO2007127207A3 (en) Fixed combination dosage forms for the treatment of migraine

Legal Events

Date Code Title Description
FG Grant or registration